Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808
   Google Scholar   
Citation:
Blood vol 110 (11) 157
Year:
2007
Type:
Abstract
Sub type:
Poster General
Funding:
NCTN
Endpoint:
Primary
Analysis:
Preliminary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
262  
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
 
Grants:
 
Corr. Author:
 
Authors:
                       
Networks:
 
Study
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-19808, CALGB-8461, CALGB-9665
Phases:
3, N/A
Keywords: